Am. J. Respir. Crit. Care Med., Volume 158, Number 3, September 1998, 939-950

Angiotensin-converting Enzyme Inhibition Delays Pulmonary Vascular Neointimal Formation

KAZUSHIGE OKADA, MATTHEW L. BERNSTEIN, WEI ZHANG, DANIEL P. SCHUSTER, and MITCHELL D. BOTNEY

Respiratory and Critical Care Division, Washington University Medical Center, St. Louis, Missouri

Primary pulmonary hypertension (PPH) is a disease characterized pathologically by pulmonary artery medial hypertrophy, adventitial thickening, and neointimal proliferation. Increasing recognition of the importance of remodeling to the pathogenesis of PPH suggests new therapeutic possibilities, but it will be necessary to (1) identify essential mediators of remodeling, and (2) demonstrate that inhibiting those mediators suppresses remodeling before new antiremodeling therapies can be considered feasible. The effect of angiotensin-converting enzyme (ACE) inhibition on pulmonary vascular remodeling was studied in a newly developed rat model in which neointimal lesions develop between 3 and 5 wk after monocrotaline injury is coupled with increased pulmonary artery blood flow after contralateral pneumonectomy. Neointimal formation was significantly suppressed at 5 wk by ACE inhibition whether it was started 10 d before or 3 wk after remodeling was initiated, although medial hypertrophy and adventitial thickening still developed. By 11 wk, the extent of neointimal formation in rats treated with ACE inhibition was similar to rats without ACE inhibition at 5 wk. Pulmonary artery pressures and right ventricular weights correlated with the extent of neointimal formation. Northern blot analysis and in situ hybridization demonstrated marked suppression of lung tropoelastin and type I procollagen gene expression in the presence of ACE inhibition. An angiotensin II type I receptor antagonist partially, but not completely, replicated the effects of ACE inhibition. These data suggest that the tissue angiotensin system may be a target for therapeutic efforts to suppress the vascular remodeling that is characteristic of primary pulmonary hypertension.

This article has been cited by other articles:

				S. Sakao, L. Taraseviciene-Stewart, C. D. Cool, Y. Tada, Y. Kasahara, K. Kurosu, N. Tanabe, Y. Takiguchi, K. Tatsumi, T. Kuriyama, et al. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells FASEB J, November 1, 2007; 21(13): 3640 - 3652. [Abstract] [Full Text] [PDF]

				N. R. Bauer, T. M. Moore, and I. F. McMurtry Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L580 - L582. [Full Text] [PDF]

				D. D. Ivy, I. F. McMurtry, K. Colvin, M. Imamura, M. Oka, D.-S. Lee, S. Gebb, and P. L. Jones Development of Occlusive Neointimal Lesions in Distal Pulmonary Arteries of Endothelin B Receptor-Deficient Rats: A New Model of Severe Pulmonary Arterial Hypertension Circulation, June 7, 2005; 111(22): 2988 - 2996. [Abstract] [Full Text] [PDF]

				R. M. Day, G. Thiel, J. Lum, R. D. Chevere, Y. Yang, J. Stevens, L. Sibert, and B. L. Fanburg Hepatocyte Growth Factor Regulates Angiotensin Converting Enzyme Expression J. Biol. Chem., March 5, 2004; 279(10): 8792 - 8801. [Abstract] [Full Text] [PDF]

				H. Eto, S. Biro, M. Miyata, H. Kaieda, H. Obata, T. Kihara, K. Orihara, and C. Tei Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury Cardiovasc Res, July 1, 2003; 59(1): 200 - 211. [Abstract] [Full Text] [PDF]

				K. Chatterjee, T. De Marco, and J. S. Alpert Pulmonary Hypertension: Hemodynamic Diagnosis and Management Arch Intern Med, September 23, 2002; 162(17): 1925 - 1933. [Abstract] [Full Text] [PDF]

				B. W. Fouty, B. Grimison, K. A. Fagan, T. D. Le Cras, J. W. Harral, M. Hoedt-Miller, R. A. Sclafani, and D. M. Rodman p27Kip1 Is Important in Modulating Pulmonary Artery Smooth Muscle Cell Proliferation Am. J. Respir. Cell Mol. Biol., November 1, 2001; 25(5): 652 - 658. [Abstract] [Full Text] [PDF]

				S. Kanno, Y.-J. L. Wu, P. C. Lee, T. R. Billiar, and C. Ho Angiotensin-Converting Enzyme Inhibitor Preserves p21 and Endothelial Nitric Oxide Synthase Expression in Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats Circulation, August 21, 2001; 104(8): 945 - 950. [Abstract] [Full Text] [PDF]

				T. NISHIMURA, J. L. FAUL, G. J. BERRY, I. VEVE, R. G. PEARL, and P. N. KAO 40-O-(2-Hydroxyethyl)-rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 498 - 502. [Abstract] [Full Text]

				J. L. FAUL, T. NISHIMURA, G. J. BERRY, G. V. BENSON, R. G. PEARL, and P. N. KAO Triptolide Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2252 - 2258. [Abstract] [Full Text]

				F. QING, T. J. McCARTHY, J. MARKHAM, and D. P. SCHUSTER Pulmonary Angiotensin-converting Enzyme (ACE) Binding and Inhibition in Humans . A Positron Emission Tomography Study Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 2019 - 2025. [Abstract] [Full Text]

				T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF]

				R. Mathew, N. Y.-T. Fan, N. Yuan, P. N. Chander, M. H. Gewitz, and C. T. Stier Jr. Inhibition of NOS enhances pulmonary vascular changes in stroke-prone spontaneously hypertensive rats Am J Physiol Lung Cell Mol Physiol, January 1, 2000; 278(1): L81 - L89. [Abstract] [Full Text] [PDF]

				N. W. Morrell, P. D. Upton, S. Kotecha, A. Huntley, M. H. Yacoub, J. M. Polak, and J. Wharton Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L440 - L448. [Abstract] [Full Text] [PDF]

				M. D. BOTNEY Role of Hemodynamics in Pulmonary Vascular Remodeling . Implications for Primary Pulmonary Hypertension Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 361 - 364. [Full Text]

				L. A. Ortiz, H. C. Champion, J. A. Lasky, F. Gambelli, E. Gozal, G. W. Hoyle, M. B. Beasley, A. L. Hyman, M. Friedman, and P. J. Kadowitz Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappa B and AP-1 Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1209 - L1221. [Abstract] [Full Text] [PDF]